The jinIX Foundation hosted a meaningful and inspiring gathering—not just to mark the launch of its non-profit initiative, but to honor Nathan Ehrlich, a young rare disease advocate whose courage and ...

The "Rituxan Hycela, Rituxan Mabthera (Rituximab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ResearchAndMarkets.com's offering.This ...

A 12-year-old British girl has recovered fully from leukemia—blood cancer—after it returned four times ever since she was ...

Scientists from the Garvan Institute of Medical Research have discovered that certain gene changes linked to leukemia may ...

Biomea Fusion is following through on a New Year’s resolution to become a metabolic-focused company. | Biomea Fusion is ...

A revolutionary bone marrow test helped save a woman’s life by detecting her leukemia relapse months before standard methods.

Living with CML can be challenging. Fortunately, these advances in CML treatment offer hope beyond daily pills.

In chronic lymphocytic leukemia (CLL), certain recurrent genetic alterations are known to influence disease progression and ...

Leahy benefitted from a clinical trial evaluating a new bone marrow test that can detect a potential leukemia relapse months ...

Dr. Xie Fangmin, founder, chairman, and CEO of Fangzhou, commented, "As a platform focused on patient-centered healthcare, we are committed to bringing innovative treatments such as Iclusig® to ...

Dr. Neha Mehta-Shah shares how patients can better understand their subtype of rare lymphoma, as well as expands on the ...

In January 2023, the Brukinsa, a next-generation BTK inhibitor, received FDA approval for chronic lymphocytic leukemia (CLL).